August 31, 2023 News by Andrea Lobo, PhD Experimental MS therapy NB-4746 to be tested in healthy volunteers Nura Bio has launched a Phase 1 clinical trial evaluating NB-4746, its investigational treatment for multiple sclerosis (MS) and several other neurological conditions, in healthy volunteers. The trial’s participants will be randomly assigned to receive single and multiple doses of NB-4746 or a placebo. The goal is to…
June 12, 2023 News by Margarida Maia, PhD FDA clears way for Phase 1 study of PIPE-791 in healthy volunteers Pipeline Therapeutics will soon launch a Phase 1 clinical study to test PIPE-791, one of its candidate treatments for multiple sclerosis (MS), in healthy volunteers. The announcement follows a go-ahead from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND) application to initiate clinical…
May 15, 2023 News by Margarida Maia, PhD 1st group of healthy volunteers dosed in Phase 1 trial of ‘Lucid-MS’ FSD Pharma has completed dosing in the first group of healthy volunteers enrolled in its Phase 1 clinical trial testing Lucid-21-302, an oral medication candidate for all types of multiple sclerosis (MS). The medication, also known as Lucid-MS, was first given to a sentinel subject ā one…
April 7, 2023 News by Lindsey Shapiro, PhD OCS-05 neuroprotective therapy for MS shows good safety profile OCS-05, a neuroprotective treatment candidate being developed by Oculis for multiple sclerosis (MS) or other causes of optic nerve inflammation, demonstrated a favorable safety and pharmacological profile in healthy volunteers, according to Phase 1 trial data. AĀ Phase 2 trial (NCT04762017), called ACUITY, is now evaluating OCS-05’s…
March 17, 2022 News by Patricia Inacio, PhD NervGen Cleared to Enroll 2nd MAD Group in NVG-291 Trial NervGen Pharma has been cleared to enroll a second group of healthy volunteers into the multiple ascending dose portion of its Phase 1 clinical trial of NVG-291, a therapeutic candidate for multiple sclerosis (MS). The trial’s Safety Review Committee approved the second group after seeing promising safety data…
January 3, 2022 News by Patricia Inacio, PhD Ascending Dosing Will Start in Trial of NVG-291 in Healthy Volunteers NervGen Pharma has received approval to begin testing multiple ascending doses of NVG-291, its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions, in a Phase 1 trial with healthy volunteers. This multiple ascending dose (MAD) part, in which participants will receive increasing doses of NVG-291…
November 5, 2021 News by Steve Bryson, PhD Nerve Repair Therapy NVG-291 Safe, Well-tolerated in Healthy People A single dose of NVG-291, a potential nerve repair therapy for multiple sclerosis (MS), was safe and well-tolerated among healthy volunteers in a Phase 1 safety trial, and was found to have favorable pharmacological properties, new data show. Given the positive results thus far, a safety committee supervising…
August 23, 2021 News by Marta Figueiredo, PhD Top-line Data on NVG-291 in Healthy Volunteers Expected This Year NervGen Pharma announced that its Phase 1 clinical trial evaluating the safety and pharmacological properties of NVG-291 ā its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions ā in healthy volunteers is going according to plan, with early top-line data expected later this year. āThe…
March 9, 2021 News by Forest Ray PhD Pipeline Testing PIPE-307 Remyelinating Compound in Healthy Volunteers Pipeline Therapeutics has initiated a Phase 1 clinical trial to investigate PIPE-307, its lead treatment candidate for multiple sclerosis (MS), in healthy volunteers. The trial (NCT04725175) will assess the compound’s safety, tolerability, and pharmacokinetics, or how the drug moves through the body. Up to 72 people, ages…
July 17, 2019 News by Joana Carvalho, PhD Phase 1 Trial of T20K, Plant Protein-derived Therapy for MS, Doses 1st Group of Healthy Men A first group of healthy volunteers in a Phase 1 trial assessing the safety and tolerability of T20K, Cyxone‘s plant protein-derived candidate for the treatment of multiple sclerosis (MS), has been dosed in a study taking place in The Netherlands, the company announced. T20K is an investigational…
June 21, 2019 News by Joana Carvalho, PhD Cyxone Launches Phase 1 Trial Assessing T20K for MS CyxoneĀ launched the first-in-human Phase 1 clinical trial assessing the effects of T20K, its new therapeutic candidate for the treatment of multiple sclerosis (MS), in healthy volunteers. The announcement came after the company received approval from the Dutch Ethics Committee and Central Commission on Research Involving Human…